In patients with CLL/SLL, first-and-second-generation BTK inhibitors have demonstrated efficacy in terms of PFS. In this special supplement to Federal Practitioner, Dr. Richard Z. Lin of Stony Brook University provides a summary of the pivotal trials that have led to FDA approvals of the first-and-second-generation BTK inhibitors and highlights real-world experiences in treating CLL and/or SLL.
